Vevzuo and Evfraxy are denosumab biosimilars approved in Europe for bone-related conditions, offering safe, effective treatments for cancer, osteoporosis, and tumor-related bone loss.

• Vevzuo prevents skeletal events and treats giant cell tumors in adults with advanced bone malignancies.
• Evfraxy reduces fractures in postmenopausal women, men with prostate cancer, and glucocorticoid-induced bone loss.
• EC approved Biocon’s biosimilars in EU/EEA, ensuring affordable access to therapies for chronic conditions.